Evidence map›Paper›PMID 40404326›Full record

ArticleBMJ open2025

Reasonable access to brief behavioural insomnia treatment among medical and psychiatric outpatients (RABBIT): a multicentre randomised controlled trial protocol.

Makie Nagai, Hiroku Noma, Masatsugu Sakata, Hitomi Oi, Jun Shigematsu, Kenta Matsumura, Toshi A Furukawa, Shun Nakajima

Abstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Makie NagaiFaculty of Pharmacy and Pharmaceutical Sciences, Josai University, Saitama, Japan.ORCID http://orcid.org/0009-0004-8595-0773
Hiroku NomaUniversity of Tsukuba, Tsukuba, Japan.ORCID http://orcid.org/0009-0000-9023-8407
Masatsugu SakataNeurodevelopmental Disorders, Nagoya City University, Nagoya, Japan.
Hitomi OiDepartment of Psychological Sciences, University of Human Environments, Matsuyama, Japan.
Jun ShigematsuFaculty of Humanities, University of Toyama, Toyama, Japan.
Kenta MatsumuraGraduate School of Health Sciences, Aomori University of Health and Welfare, Aomori, Japan.ORCID http://orcid.org/0000-0002-4271-1543
Toshi A FurukawaOffice of Institutional Advancement and Communications, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0003-2159-3776
Shun NakajimaInternational Institute for Integrative Sleep Medicine (WPI-IIIS), Tsukuba Daigaku, Tsukuba, Japan shun.nkjm@gmail.com.ORCID http://orcid.org/0000-0002-2992-195X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionInsomnia is a significant global health issue associated with substantial economic costs. International guidelines recommend cognitive behavioural therapy for insomnia (CBT-I) as the first-line treatment for chronic insomnia; however, pharmacotherapy remains more common in clinical practice. Maintaining the effectiveness while reducing the time and frequency of CBT-I is essential for its implementation. We conducted a randomised controlled trial (RCT) to evaluate the effectiveness of a brief behavioural treatment for insomnia (BBTI) that focuses on sleep restriction and stimulus control (SC)-both established as effective standalone interventions. This article presents the study protocol to examine whether adding BBTI to treatment as usual improves outcomes in patients with chronic insomnia. METHODS AND ANALYSIS: We will conduct a multicentre RCT. We will randomly assign patients with chronic insomnia to two groups (BBTI vs sleep hygiene) in a 1:1 ratio. The BBTI consists of three 15 min sessions over 4 weeks delivered by healthcare professionals following a detailed manual. The primary outcome is the Insomnia Severity Index at 8 weeks. Secondary outcomes include sleep latency, wake after sleep onset, total sleep time, sleep efficiency, Generalized Anxiety Disorder-7, Patient Health Questionnaire-9 and EuroQol-5D-5L. We will conduct the assessment at weeks 0 (baseline), 4 (end of intervention), 8 (post-intervention, primary endpoint) and 12 (follow-up). We will assess each sleep variable from the sleep diary at weeks 0 and 8. The analysis will be performed on an intention-to-treat basis. ETHICS AND DISSEMINATION: This study has been approved by the Ethics Committee for Clinical and Epidemiological Research of Toyama University (approval no. R2023152). TRIAL REGISTRATION NUMBER: UMIN000052911; pre-results.

Indexed as

Cognitive Behavioral TherapySleep Initiation and Maintenance DisordersAdultFemaleHumansMaleMulticenter Studies as TopicOutpatientsRandomized Controlled Trials as TopicTreatment OutcomeInsomniaProtocols & guidelinesPsychosocial InterventionRandomized Controlled TrialSleep medicine

Identifiers

PMID40404326
PMCPMC12096993

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.